Previous studies demonstrate that >45% of these patients will recur after a 20-year follow-up period [3] and with approximately 6% of patients being diagnosed with de novo stage IV disease [4], the result is a growing burden of HR+/HER2-advanced-stage BC (ABC) patients, representing 54% of all stage IV cases in Chile [5]. This evidence concerns the gene ERBB2 and breast cancer.